Targeting oncogenic KRAS in non-small cell lung cancer with EGFR aptamer-conjugated multifunctional RNA nanoparticles

This publication has 55 references indexed in Scilit:

• Fabrication of pRNA nanoparticles to deliver therapeutic RNAs and bioactive compounds into tumor cells
  Nature Protocols, 2013
• Mutations in Specific Codons of the KRAS Oncogene are Associated with Variable Resistance to Neoadjuvant Chemoradiation Therapy in Patients with Rectal Adenocarcinoma
  Annals of Surgical Oncology, 2013
• Thermodynamically stable RNA three-way junction for constructing multifunctional nanoparticles for delivery of therapeutics
  Nature Nanotechnology, 2011
• Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis
  Nature, 2011
• Hallmarks of Cancer: The Next Generation
  Cell, 2011
• Knockdown of Oncogenic KRAS in Non–Small Cell Lung Cancers Suppresses Tumor Growth and Sensitizes Tumor Cells to Targeted Therapy
  Molecular Cancer Therapeutics, 2011
• In vitro assembly of cubic RNA-based scaffolds designed in silico
  Nature Nanotechnology, 2010
• Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors
  Oncogene, 2009
• Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer
  The Lancet Oncology, 2008
• EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
  Proceedings of the National Academy of Sciences, 2004